The American Society for Clinical Oncology (ASCO) has chosen Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, of Dana-Farber/Brigham and Women's Cancer Center, to lead the prestigious cancer organization as its president in 2026.
Mittendorf, a noted surgical oncologist, will take office as president-elect during the ASCO Annual Meeting in Chicago in June 2025.
"I am grateful for the opportunity to lead ASCO at this important time in cancer care," says Mittendorf. "Together, our members worldwide work to champion innovative research, foster education, and advocate for policies that ensure every patient receives equitable, high-quality care. I am excited to collaborate with this extraordinary community to advance our shared mission of conquering cancer and improving lives."
Mittendorf is currently director of the Breast Immuno-Oncology program and co-leader of the Parker Institute for Cancer Immunotherapy at Dana-Farber. She is the Robert and Karen Hale Endowed Chair in Surgical Oncology and vice chair for Research in the Department of Surgery at Brigham and Women's Hospital, and co-leader of the Breast Program for the Dana-Farber/Harvard Cancer Center.
Her extensive volunteer history with ASCO includes serving on the ASCO Board of Directors from 2019-2023, when she also served as the Society Treasurer from 2022-2023. She is also a past chair of the Conquer Cancer Grants and Awards Selection Committee, and past member of the Annual Meeting Scientific Program Committee and Best of ASCO Planning Committee.
Mittendorf will be the seventh Dana-Farber affiliated physician to serve as president since ASCO was founded in 1964. The previous six were Emil Frei, MD, 1968-69; George P. Canellos, MD, 1993-94; Karen H. Antman, MD, 1994-95; Robert Mayer, MD, 1997-98; Bruce Johnson, MD 2017-18, and Monica Bertagnolli, MD, 2018-19.
